Expert Interviews

A panel of experts in vaccination share their thoughts on the optimal timing and administration of an influenza vaccine for the general public.

Dr Wendy Wright reviews the differences between influenza strains and the rationale for the inclusion of multiple viral strains within flu vaccines.

The goal of a PM&R physician is to identify the source of function-limiting pain and then develop the best plan for each patient to return them to their lives.

Sandra Christensen, MSN, ARNP, gives her top strategies on patient selection for treatment with antiobesity medications and how to choose the right drugs for patients.

Roger S. McIntyre, MD, FRCPC, discusses the history of psychiatry and the conventional treatment and response times, leading into the current treatment armamentarium for treatment of major depressive disorder (MDD).

Carmen Kosicek, MSN, PMHNP-BC, reviews the definition of “rapid-acting” therapies as well as their role in treating major depressive disorder (MDD).

Amy Houtrow, MD, PhD, MPH, considers the impact of poverty on childhood disability and talks about opportunities to breach barriers to health care access.

Renowned pediatric rehabilitation physician Amy Houtrow, MD, PhD, MPH, highlights the scope of the specialty and its core objectives.

Neil Skolnik, MD, reviews the currently available vaccine technologies, highlighting their mechanisms of action and individual delivery methods.

A panel of experts in vaccination uptake strategies discuss their best practices for empowering their patients to obtain flu vaccines and discuss how to personalize these conversations.

How can a nearby physiatrist help your patient with hypertension? If comorbid arthritis has the person couchbound, a consult and some PT could go a long way.

The patient with neck pain might be better off referred to a physiatrist for additional evaluation and possibly treatment, according to PM&R physician Atul Patel, MD.

A member of the board of the American Academy of Physical Medicine & Rehabilitation highlights the breadth of his practice.

Obesity specialist Sandra Christensen, MSN, ARNP, compares the benefits and drawbacks among older antiobesity drugs and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

Jacinda Abdul-Mutakabbir, PHARMD, MPH, AAHIVP, leads a conversation on the importance of vaccination in the defense and protection against viral infections, such as the flu.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, shares her thoughts on the changing perception of influenza and influenza vaccination post the COVID-19 pandemic.

Experts conclude their discussion on the efficacy and safety study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on possible dosing strategies and key takeaways from this study.

Experts discuss the results of the safety and efficacy study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on the adverse events observed in the test and placebo groups.

Experts discuss how infant weight related to efficacy outcomes of nirsevimab for Respiratory Syncytial Virus (RSV), providing their clinical expertise on why this may have occurred and what improvements can be made to mitigate these differences.

Experts discuss data relating to the strains of Respiratory Syncytial Virus (RSV) and how clinicians should consider them in relation to the efficacy of nirsevimab.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, continue their discussion on the results of nirsevimab for Respiratory Syncytial Virus (RSV) and offer insights on how this may change therapeutic approaches in the future.

Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, discuss the initial efficacy data of the study on nirsevimab for Respiratory Syncytial Virus (RSV) and how it compared to placebo.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the patient population of the safety and efficacy study on nirsevimab for Respiratory Syncytial Virus (RSV).

Tina Tan, MD, FAAP, FIDSA, FPIDS, presents the background, objectives, and methods of a recent study on the efficacy and safety of nirsevimab for Respiratory Syncytial Virus (RSV) in late-preterm and term infants.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the prevalence of Respiratory Syncytial Virus (RSV) and prior preventative gaps. They also discuss the recent FDA-approval of nirsevimab for late-preterm and term infants.

Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, introduce the objectives of their discussion and background information on Respiratory Syncytial Virus (RSV) and nirsevimab.

Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

"Keep the vaccination conversation going this year, even though your patients, and probably you, too, have grown tired of the issues and your team is worn out."

SARS-CoV-2, influenza, and respiratory syncytial virus are all targets this flu season for family physician Chuck Vega, MD, who says he's "going for all 3."